|Bid||0.0000 x 1200|
|Ask||0.0000 x 1200|
|Day's Range||2.9100 - 3.0700|
|52 Week Range||1.0300 - 10.9500|
|Beta (5Y Monthly)||2.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 27, 2020 - Nov 02, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Dec 13, 2012|
|1y Target Est||16.00|
Cassava Sciences (SAVA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
AUSTIN, Texas, July 09, 2020 -- Cassava Sciences, Inc. (Nasdaq:SAVA), a biotechnology company focused on Alzheimer’s disease, today announced that its lead neuroscientist,.
Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that the Company will be added to the Russell 2000® and Russell 3000® Indexes, effective after the close of the U.S. markets on Friday, June 26, 2020. “We are pleased Cassava Sciences is being added to these stock market indexes and are looking forward to building further awareness with the investor community about our focus on Alzheimer’s disease,” said Remi Barbier, President & CEO. “In addition, we look forward to announcing comprehensive study results from our Phase 2b study in approximately Q3 this year.”